|
End-of-day quote
Taipei Exchange
2026-08-13
|
5-day change | 1st Jan Change | ||
| 22.80 TWD | -0.22% |
|
-1.94% | -11.46% |
| Aug. 02 | GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021 | CI |
| Jun. 10 | Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8 | CI |
Chart: Technical Analysis
Stock exchange
Taipei Exchange
4168 22.80 NT$
-0.22%
2.11M
NT$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Taipei Exchange
| 4168 | 22.80TWD | -0.22% | 2.11M NT$ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 23.85 | 24.6 | 28.9 |
| Spread/Res. | -4.40% | -7.32% | -21.11% |
| Spread/Supp. | +3.40% | +3.40% | +9.62% |
| Support | 22.05 | 22.05 | 20.8 |
- Stock Market
- Stocks
- 4168 Stock
- Charts GlycoNex Incorporation
Select your edition
All financial news and data tailored to specific country editions
